Home › Weight Loss › Weight Loss Injections UK › Best Weight Loss Injections UK

Best Weight Loss Injections UK 2026

Searching for the best weight loss injection is really a search for the one that is best for you — and those are different questions. The licensed treatments available in the UK have different mechanisms, different dosing schedules, different side effect patterns and different costs, and the option that produces the strongest result for one person is frequently not the one a prescriber would choose for another with the same BMI.

This guide explains how UK prescribers actually make that decision. It covers the licensed injectable options and the oral alternative — included because people comparing injections frequently ask about non-injectable routes — what the head-to-head evidence shows and what it does not, how factors like type 2 diabetes, PCOS, injection frequency, prior treatment history and tolerance change the picture, and how to judge a provider before you commit. It does not tell you which medicine to take, because no page can — that decision requires a clinician who has seen your full medical history.

✍️ Written by Shadeia Younis, Superintendent Pharmacist (GPhC No. 2052119) and the Slinic Clinical Team
Last medically reviewed: 3rd August 2026 · Last updated: 3rd August 2026

---

Which weight loss injection is right for you?

The honest answer is that this cannot be determined from a webpage, and any page that tells you otherwise is selling rather than advising. What a page can usefully do is show you the factors that actually drive the decision, so that you arrive at your consultation understanding why a prescriber recommends what they recommend.

In practice, the choice between licensed weight management injections in the UK turns on six things.

1. Your medical history

This is the largest single input and the one patients most often underestimate. A history of pancreatitis, gallbladder disease, severe gastrointestinal disease, diabetic retinopathy, kidney or liver impairment, thyroid disease, or an eating disorder all change what is appropriate — sometimes ruling treatment out entirely, sometimes changing which option is preferred, sometimes simply requiring closer monitoring.

2. Whether you have type 2 diabetes

Diabetes changes the route, the priorities and the monitoring. It can also make you eligible at a lower BMI. If you take insulin or a sulfonylurea, adding a GLP-1 based medicine without adjusting those doses creates a genuine hypoglycaemia risk, so coordination with whoever manages your diabetes is a safety requirement rather than a courtesy.

3. Every other medicine you take

Including over-the-counter products, herbal remedies and supplements. Delayed gastric emptying alters how quickly oral medicines are absorbed, which matters most where timing or a narrow therapeutic range is involved. Oral contraception is a specific and frequently missed interaction.

4. Your treatment history

Whether you have used a GLP-1 medicine before, what dose you reached, how well you tolerated it, whether you stopped and why, and how long ago. Someone restarting after a nine-month gap is in a different clinical position from someone starting for the first time, even if their BMI is identical.

5. Practical fit

Weekly injection or daily tablet. Whether you travel frequently and can maintain cold chain. Whether you can commit to the cost at a maintenance dose rather than a starting dose. Whether you have a planned surgery, a pregnancy plan, or a fasting period coming up. These are not minor considerations — they are the things that determine whether treatment is sustained long enough to work.

6. What you can tolerate

Gastrointestinal side effects are the main reason people stop treatment early. Tolerance is individual, largely unpredictable in advance, and managed far more by titration pace than by medicine choice. Our week-by-week side effects timeline sets out what is typical and when.

---

The licensed weight-management treatments in the UK compared

Four licensed weight-management products are compared below, followed by Ozempic, because it frequently appears in weight-loss searches despite holding a different UK licence.

Why Ozempic keeps appearing in weight loss searches

Ozempic contains semaglutide, the same active ingredient as Wegovy, but its UK licence is for type 2 diabetes rather than weight management10. Prescribing it for weight loss is off-label, and demand driven by weight loss has contributed to supply pressure affecting people who need it for diabetes. If semaglutide is clinically appropriate for weight management, Wegovy is the licensed product.

Dose ranges are not comparable between products

A frequent source of confusion: tirzepatide is dosed from 2.5 mg to 15 mg, while injectable semaglutide for weight management starts at 0.25 mg and escalates to a 2.4 mg weekly maintenance dose. A higher 7.2 mg weekly dose is also licensed in the UK for certain adults with obesity, subject to the licensed criteria and clinical assessment: the MHRA authorised the 7.2 mg maximum weekly dose in January 20268, initially administered as three 2.4 mg doses on the same day, followed by approval of a single-dose 7.2 mg pen in April 2026. That higher dose is licensed for adults with a BMI of 30 or above. It does not apply to patients with a BMI below 30, or to those using semaglutide to reduce cardiovascular risk. Full dosing detail is on our Wegovy UK page. These dose numbers describe completely different molecules and cannot be compared. A higher number does not indicate a stronger medicine, and there is no published dose-equivalence table for weight management that allows a direct conversion between them.

---

How UK prescribers actually choose between treatments

Patients often imagine the decision as a ranking exercise — that there is a best option and the prescriber’s job is to confirm you qualify for it. In practice the reasoning runs almost the opposite way. The prescriber starts with everything that would make a given treatment inappropriate, and what remains is the shortlist.

Step one: is any pharmacological treatment appropriate?

This comes before choosing between products. It covers whether you meet the licensed criteria, whether anything in your history is a contraindication, whether a symptom needs investigating first, and whether your relationship with food and your body means an appetite-suppressing medicine could do harm. A prescriber who skips this step is not doing the job.

Step two: does anything rule a specific option out?

Frequency of administration, existing medicines, planned pregnancy, planned surgery, prior intolerance, current supply position, and whether you can maintain refrigeration all narrow the field before efficacy is considered at all.

Step three: what does the evidence support for someone in your position?

Trial data describes averages across studied populations. It is genuinely useful for setting expectations and for understanding what a class of medicines can achieve. It is much less useful for predicting an individual result, and prescribers treat it accordingly.

Step four: what can you actually sustain?

The most effective medicine in a trial is not effective for a patient who stops after six weeks because of cost or side effects. Realistic assessment of what someone can maintain for twelve months is a legitimate and underrated part of the decision.

---

Tirzepatide: what the evidence shows

Tirzepatide is a dual agonist, activating both GIP and GLP-1 receptors. Most other weight management injections available in the UK act on GLP-1 alone. Both hormones are produced naturally in the gut in response to food and form part of the signalling system that tells the brain you have eaten enough.

The main trials

SURMOUNT-11 studied adults with obesity, or overweight with a weight-related complication, without type 2 diabetes, over 72 weeks alongside lifestyle intervention. Mean weight reduction was approximately 15% at 5 mg, approximately 19.5% at 10 mg and approximately 20.9% at 15 mg, compared with approximately 3.1% on placebo. Limitation: participants received structured support at trial intensity, and people with type 2 diabetes were excluded.

SURMOUNT-32 examined tirzepatide following an intensive lifestyle intervention lead-in — that is, in people who had already lost weight through lifestyle change alone. It found further significant reduction. Limitation: the population had already demonstrated they respond to lifestyle intervention, which may not generalise.

SURMOUNT-434 is the most important trial for anyone thinking about stopping. Participants took tirzepatide for 36 weeks, then were randomised either to continue or switch to placebo for a further 52 weeks. Those who continued lost a further 5.5% of body weight measured from week 36, while those switched to placebo regained 14.0% measured from week 36 — not from original baseline.

For full detail on eligibility, dosing, side effects and cost, see our complete Mounjaro UK guide.

---

Semaglutide: what the evidence shows

Semaglutide is a GLP-1 receptor agonist, licensed in the UK for weight management as Wegovy in both injectable and oral form. It has a longer real-world track record in weight management than tirzepatide, having been available for longer, and a correspondingly larger body of published safety data across a wider range of patient groups.

What the trials show

The STEP programme6 established semaglutide’s efficacy for weight management, with mean reductions in the region of 15% over 68 weeks at the 2.4 mg maintenance dose alongside lifestyle intervention. The SELECT trial7 subsequently examined cardiovascular outcomes in people with established cardiovascular disease and overweight or obesity without diabetes, and found a reduction in major adverse cardiovascular events.

That cardiovascular finding is clinically significant and is one of the reasons semaglutide may be preferred in specific patient groups — not because it produces greater weight reduction, but because the outcome data addresses a different question.

For full detail, see our Wegovy UK guide.

---

The head-to-head data — and what it does not tell you

SURMOUNT-55 compared tirzepatide directly against semaglutide in 751 adults with obesity and without diabetes over 72 weeks. Mean weight reduction was approximately 20.2% with tirzepatide versus approximately 13.7% with semaglutide, with a greater reduction in waist circumference as well.

This is a genuine finding from a properly conducted trial, and it is the single most cited comparison in this field. It deserves to be reported accurately — including its limitations.

The figures above are the treatment-regimen estimand reported in the published New England Journal of Medicine paper. Regulatory summaries and product information may report slightly different figures for the same trial, because they use different statistical estimands and analysis populations. Where you see different numbers quoted elsewhere, that is usually the explanation rather than a contradiction.

A difference in group averages is not a ranking that applies to individuals. Plenty of people achieve excellent results on semaglutide, including people who did not tolerate tirzepatide. The reverse is also true. Response varies substantially between individuals for reasons that are not fully understood, and neither medicine works well for everyone.

What to take from this. Use the head-to-head data to understand what this class of medicine can achieve, not to pre-select your treatment. Bring the question to your consultation instead — a prescriber can tell you whether the difference is relevant to your situation, and whether anything in your history makes one more appropriate than the other.

---

Mounjaro or Wegovy: the practical differences

Most people arriving at this page are really deciding between these two. The table below sets out the practical distinctions rather than declaring a winner, because the factors that decide it are individual.

Neither column is a recommendation. Both medicines produce good results in some people and poor results in others, and prior tolerance, medical history, practical fit and cost frequently outweigh the average-efficacy difference. Our dedicated Mounjaro versus Wegovy comparison covers this in full detail.

---

Where Saxenda fits now

Liraglutide, marketed as Saxenda, is licensed in the UK for weight management and was the first GLP-1 based option widely available for this purpose. It is used considerably less often now, and it is worth understanding why rather than simply omitting it.

Daily rather than weekly. Saxenda is a once-daily injection. That is seven injections a week rather than one, which is the main practical reason patients and prescribers moved away from it as weekly options became available.

Lower average weight reduction. The published evidence for liraglutide shows meaningful but smaller mean weight reduction than either semaglutide or tirzepatide in their respective trials.

Shorter duration of action. This is occasionally an advantage rather than a drawback. A shorter-acting medicine clears more quickly, which can matter where a prescriber wants the option to stop the effect relatively rapidly, or where a patient has had difficulty tolerating longer-acting agents and a more controllable option is preferred.

When it may still be considered. Prior good response to liraglutide specifically, supply issues affecting alternatives, or a clinical preference for a shorter-acting agent in a particular patient. These are genuine but relatively uncommon situations.

If you have used Saxenda before, mention it at your assessment. Prior response to one GLP-1 medicine is useful information even when the plan is to use a different one.

---

Starting treatment for the first time

If you have never used a GLP-1 based medicine, the most consequential decisions are not about which product you take. They are about how you start.

Titration matters more than choice of medicine

Every licensed weight management injection begins at a low introductory dose and increases in defined steps, with a minimum interval at each. That schedule exists specifically to improve tolerability. Almost all the difference between someone who settles into treatment comfortably and someone who abandons it in week three comes down to how that titration is handled.

Three principles apply regardless of which medicine you are prescribed.

The minimum interval is a minimum, not a schedule. Product information sets the earliest point at which a dose may be increased. It does not say every patient should increase at that point. Staying longer at a dose is a legitimate clinical decision and frequently the right one.

Increases should follow a review, not a calendar. Escalating while significant side effects persist usually makes those side effects worse without adding benefit. A provider that increases your dose automatically every four weeks without asking how you are tolerating it is running an administrative process, not a clinical one.

Steps must not be skipped. Jumping a titration step without prescriber authorisation substantially increases the risk of adverse effects and does not accelerate results. See our guide to dose titration and the full dosing schedule.

What the first four weeks usually look like

---

Injections versus tablets

A licensed oral option now exists for weight management, which changes the picture for people whose main barrier is needles. It is not simply an injection in tablet form, and the practical differences matter.

Our oral semaglutide guide covers administration, dosing and practical considerations in full, and we compare the two routes directly in our pill versus injection guide.

Choosing between oral and injectable semaglutide

These contain the same active ingredient, so the choice is not about which medicine but about which route you can sustain.

The oral route has strict administration requirements. It is taken first thing in the morning in a fasted state, with a specific small volume of water, and you must then wait before eating, drinking or taking other oral medicines. Absorption depends on following that properly.

Other oral medicines complicate it. If you take thyroid replacement, which has its own fasted-morning requirement, or several other morning medicines, sequencing becomes genuinely difficult. Raise this at assessment.

Weekly dosing is more forgiving. One missed weekly injection is recoverable within a defined window. Missed daily doses accumulate quietly and are the most common reason oral treatment underperforms.

Storage and travel are simpler orally. No cold chain, no sharps, no needle supply to plan around.

How the injection devices differ

Device design is a small detail that has a disproportionate effect on whether people persist with treatment, and it is rarely discussed before starting.

The Instructions for Use supplied with your specific pen are the authoritative source and should be read fully before the first injection. If you are unsure, ask the pharmacy to talk you through it rather than working it out from a video. Our KwikPen administration guide covers the sequence step by step, and we have separate advice on reducing injection discomfort.

Storage and travel compared

If cold chain is genuinely difficult for your circumstances — frequent travel, no reliable fridge, long commutes in heat — say so at assessment. It is a legitimate factor in choosing a route and it is better raised before treatment than after a pen has been spoiled. See our storage guide and our travel and cold chain guide.

---

If you have type 2 diabetes

Type 2 diabetes changes this decision more than any other single factor, and it is the area where patients most often go wrong by trying to shortcut the process.

Different route

Tirzepatide and semaglutide both hold separate UK licences for type 2 diabetes and for weight management. When prescribed for diabetes, that happens through diabetes care — usually your GP practice or a diabetes specialist — as part of managing blood glucose. That route is not phased in the way the NHS weight management programme is, so access is often quicker if you meet the criteria.

Different priorities

In diabetes prescribing, the focus is glycaemic control, HbA1c and cardiovascular risk. Weight reduction is a welcome secondary benefit rather than the primary aim. That changes which medicine is preferred and how success is measured. See our NHS Mounjaro guide for how the two routes differ in practice.

Different monitoring, and a real safety issue

Adding a GLP-1 based medicine to insulin or a sulfonylurea without adjusting those doses creates a genuine hypoglycaemia risk. This is the most important safety point in this section.

Private weight-management prescribing for someone with type 2 diabetes is possible and common — BMI 27 or above with type 2 diabetes meets the licensed criteria — but it requires your HbA1c, current medicines and diabetes management history to be reviewed as part of the assessment.

The retinopathy point that gets missed. Rapid improvement in blood glucose control has been associated with temporary worsening of diabetic retinopathy. If you have diabetes and existing eye disease, this is directly relevant to how quickly treatment is escalated, and it is a reason a prescriber may titrate more slowly than you would like.

Mention any eye disease at assessment even if it feels unrelated to weight management. It is one of the more common omissions we see.

---

If you have PCOS

Polycystic ovary syndrome is not itself on the licensed list of qualifying conditions for treatment at BMI 27 to 29.9. However, insulin resistance, prediabetes and raised BMI commonly accompany it, and those may qualify.

Two things are worth knowing before you start, and the second is frequently overlooked.

Weight reduction can restore ovulation in people who were not previously ovulating. For some people that is a welcome outcome. For others it means fertility returns unexpectedly.

These medicines are not recommended in pregnancy. Combined with the point above, that makes contraception planning genuinely important rather than a box-ticking exercise.

---

If you do not have diabetes or another qualifying condition

If your BMI is 30 or above, no additional weight-related condition is required for private eligibility. This is the largest group of people seeking treatment, and the decision is generally more open than it is for people with significant comorbidity — which is a mixed blessing, because it means the choice rests more heavily on tolerance, practicality and cost than on clinical constraint.

Points that matter for this group specifically:

The trial populations most closely match you. SURMOUNT-1 and SURMOUNT-5 both studied adults with obesity without type 2 diabetes, so the published figures are more directly applicable than they are for other groups. They remain averages, but they are averages from a population resembling yours.

Ethnic background may affect your threshold. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, a lower BMI threshold is commonly applied — usually reduced by around 2.5 kg/m² — because cardiometabolic risk occurs at lower BMI in these populations. NHS England applies this adjustment in its own commissioning guidance.

Eligibility is not approval. Meeting the BMI threshold does not mean treatment is appropriate. A prescriber can still decline based on your history, a symptom needing investigation, or the overall clinical picture. A provider that guarantees approval before assessing you is telling you something important about how seriously it takes the assessment.

---

If side effects are your main concern

This is one of the most common reasons people ask which treatment is best, and the honest answer is not the one most pages give.

Side effect profiles across GLP-1 based weight management treatments are broadly similar. They are predominantly gastrointestinal — nausea, diarrhoea, vomiting, constipation, abdominal discomfort, reflux, reduced appetite, burping and fatigue. Most appear in the first weeks or after a dose increase, and most settle as the body adjusts.

What differs meaningfully between people is not usually the medicine. It is:

How fast you titrate. The single largest modifiable factor. Slower escalation, with longer at each step, substantially improves tolerance for most people.

What and how you eat. Portion size, meal composition and eating pace affect nausea more than most patients expect. Very fatty and fried foods are a reliable trigger in the days after a dose.

Hydration. Reduced appetite frequently reduces fluid intake without you noticing, and mild dehydration worsens nausea, fatigue and constipation simultaneously.

Whether anyone reviews you. Side effects that are managed early rarely become the reason someone stops. Side effects that are ignored for six weeks usually do.

---

What actually drives the cost of treatment

Private weight management treatment in the UK generally ranges from around £120 to over £300 per month depending on dose, product and provider. That range is wide because providers structure pricing very differently, and the advertised figure is frequently not what you end up paying.

Working out total annual affordability

The calculation worth doing before you start, rather than in month four when it becomes urgent.

Start from the maintenance dose, not the starting dose. Most people escalate over the first few months, so the relevant figure is the price at the dose you are likely to settle on, not the one advertised.

Multiply by twelve, then add. Delivery charges across the year. Needles and sharps bins if not supplied. Any consultation or review fees. Any subscription minimum you would be committed to.

Then ask what happens if you need to pause. Cancellation terms, whether a subscription continues, and whether restarting requires a new assessment fee.

Compare that total figure between providers. Not the headline monthly price, and not the first-month discounted price.

Starting and stopping repeatedly because of cost is clinically worse than not starting, and it is a common and avoidable pattern. If affordability is genuinely marginal, say so at your assessment — it is a legitimate part of the clinical conversation, not something to be embarrassed about.

For a full price comparison across UK providers including hidden fees, see our cheapest Mounjaro UK guide.

---

NHS versus private treatment

Three things get conflated here, and separating them makes the picture much clearer.

The licence says who a medicine can lawfully be prescribed to.

The NICE recommendation13 says who the NHS should fund it for.

The NHS rollout says who can actually get it right now — and this is considerably narrower than either of the above, because a funding variation allows phased implementation over approximately 12 years15 to manage the scale of demand.

NHS weight management services provide high-quality care, and where you qualify and can access one without a prohibitive wait, that route is well worth pursuing. The reason many people go private is availability rather than quality: the current phased criteria simply exclude the majority of people who meet the licensed threshold.

NHS England has asked patients not to contact their GP to request weight-loss injections — under the current arrangement, eligible patients are identified from GP records and contacted directly. Arrangements differ in Scotland, Wales and Northern Ireland, which set their own commissioning positions.

See our NHS weight loss injections guide for current criteria and cohort detail.

---

Choosing a provider: what separates them

It is worth separating two things that are routinely conflated in advertising.

The medicine is the same molecule regardless of which UK pharmacy supplies it, provided it is genuine, licensed stock obtained through the authorised supply chain. A pen dispensed by one registered pharmacy is pharmacologically identical to a pen dispensed by another.

The programme is everything around the medicine: the quality of the clinical assessment, who reviews your case, whether anyone checks in with you, how side effects are managed, what happens when progress stalls, and what support exists when you want to stop. This varies enormously between providers, and it is where the actual difference in patient outcomes lies.

When patients compare providers on price alone, they are comparing the identical component and ignoring the variable one. That works in both directions — a higher price does not automatically indicate better clinical support either.

What to actually check

Confirm it is a registered UK pharmacy. Find the GPhC registration number, then look it up on the GPhC register12 yourself. A number displayed on a website proves nothing until you verify it independently.

Check who owns and runs it. A legitimate pharmacy names its superintendent pharmacist and provides a real UK address and a working phone number. Be cautious of any provider contactable only through a web form.

Confirm a genuine clinical assessment takes place. You should be asked detailed questions about your medical history, current medicines and pregnancy status. A three-question form is not a clinical assessment. Our guide to how online consultations work explains what a proper assessment involves.

Check who the prescriber is. They should be a UK-registered doctor, pharmacist prescriber or nurse prescriber, registered with the GMC, GPhC or NMC.

Check how the medicine is stored and delivered. Injectable treatments require refrigeration before first use. Ask how cold chain is maintained in transit.

Read the payment terms before you order. Is this a subscription? Can you cancel? Does the price change after the first month? Are there consultation, prescription or delivery charges added at checkout?

Check what ongoing clinical support is included. Who reviews your dose increases? Is there anyone to contact when side effects appear? Is there a review before each repeat supply?

Check the regulatory signals in the right order. GPhC registration is the statutory requirement and the one that matters most. LegitScript certification is a useful additional signal but is a private certification scheme, not a substitute for statutory regulation.

Compare us directly: Slinic vs Boots, Slinic vs MedExpress, Slinic vs Juniper, Slinic vs VOY, Slinic vs Simple Online Pharmacy.

---

Red flags before you buy

The demand for weight-loss injections has created a substantial illegitimate market. Treat the following as absolute red flags.

Our full guide to red flags when buying weight loss injections online covers how to verify a supplier before you pay.

If you have already bought a product outside the regulated route and used it, speak to a pharmacist or your GP. If you have symptoms that concern you, contact NHS 111, or 999 in an emergency.

---

Switching between treatments

Moving between GLP-1 based treatments is common and done regularly, but it is a clinical process rather than an administrative one.

There is no published dose-equivalence table for weight management that allows a direct conversion between medicines. Any switch is a clinical judgement based on your current dose, how long you have taken it, how you tolerated it and your response.

The two must never overlap. This is the most important safety point in this section.

It must never be self-managed. The appropriate starting dose on the new medicine depends on your treatment history, and getting it wrong in either direction causes problems — too high produces avoidable side effects, too low wastes weeks.

Switching provider is different from switching medicine

Patients transfer between providers regularly, usually because of cost, service quality, supply reliability or subscription terms. It is a normal thing to do and does not require starting treatment again from scratch.

You will need to evidence your current treatment — a dispensing label, prescription record, letter from your previous provider, or an order history showing dose and dates. Without evidence of what you have been taking, a prescriber cannot safely continue you at a higher dose. A prolonged gap may mean restarting lower, and that is a safety decision rather than an administrative one. If you are moving to us from elsewhere, our guide on switching provider sets out what evidence to bring.

See our guides on switching from Wegovy to Mounjaro and switching from Mounjaro to Wegovy.

---

Restarting after a break

If you have stopped treatment for a period — through supply problems, cost, side effects, travel or simply pausing — restarting is not always as straightforward as picking up where you left off.

Tolerance can reduce during a break. The gradual titration schedule exists because the body adapts over time. After a gap, that adaptation may have partly reversed, which means returning directly to your previous dose can produce side effects considerably worse than you experienced before.

How much this matters depends on how long the gap was, what dose you were on, how well you tolerated it, and what has changed about your health in the meantime.

Restart decisions are individual. A short gap after months at a stable dose is a different situation from a long gap after a rapid escalation. Providers set their own restart protocols, which is why one may restart you differently from another.

Do not simply resume your previous dose without a review. See our guide to restarting safely.

---

When treatment is not working

Two different situations get conflated here, and they have different answers.

A plateau

Weight loss is rarely linear. Periods where the scales stall for two to four weeks are common and usually resolve. Contributing factors include fluid shifts, hormonal cycles, changes in bowel habit, reduced energy expenditure as body mass falls, and gradual upward drift in intake as the body adapts.

What helps: reviewing actual intake honestly rather than from memory, protein and resistance training, checking whether portion sizes have crept up as appetite suppression has become familiar, and measuring weekly at a consistent time rather than daily. Missed doses are a common hidden cause — see our guide on what to do after a missed dose.

Genuine non-response

Different situation. If there has been no meaningful change after several months at an adequate dose, taken consistently, that warrants a proper review rather than persistence.

A review should consider whether the dose is adequate or whether you are still early in titration, whether doses have been missed, whether another medicine or condition is contributing, whether something needs investigating, and whether a different treatment or approach would suit you better.

The starting dose is not a maintenance dose. A large proportion of people who conclude that treatment is not working for them are still on the introductory dose, which exists to introduce the medicine gradually rather than to produce a result. Judging efficacy at that stage is judging it too early.

Equally, escalating to the maximum dose is not the answer to every disappointing result. If intake has not actually fallen, a higher dose will not change the arithmetic. That is a conversation worth having honestly at review rather than assuming more medicine is the fix.

Related reading: how to break a weight-loss plateau and why the starting dose may not be working.

---

Long-term treatment and maintenance

Most conversations about weight loss injections focus on starting. The harder question is what happens after the first year, and it is worth thinking about before you get there rather than after.

Three broad paths

Continuing at a maintenance dose. For many people with a chronic condition, continued treatment is the appropriate answer, in the same way it would be for blood pressure. SURMOUNT-4 supports this: continued treatment maintained and extended the result, while stopping was commonly followed by regain.

Reducing to a lower dose. Some people maintain well on less. This is a prescriber decision based on your response, not something to trial independently.

Stopping with a maintenance plan. Possible, and considerably more likely to work where sustainable eating patterns, regular activity and resistance training are already established rather than being started at the point of stopping.

Why this belongs in the choosing decision

Because the medicine that produces the best twelve-week result is irrelevant if you cannot sustain it for twelve months. Cost, tolerance and practicality all compound over time, and the treatment you can maintain will outperform the one you abandon in month four. Factor the long term into the initial choice rather than treating it as a problem for later.

---

When treatment is not the right answer

A page like this one has an obvious commercial incentive to present treatment as the solution. It is not always.

If your BMI is below the licensed threshold, treatment is not appropriate, and no legitimate provider will supply it. The evidence base is in people with obesity, or overweight with complications.

If your relationship with food or your body is the primary problem, a medicine that suppresses appetite may make things worse rather than better. Current or past eating disorders need addressing with appropriate support first, and a good assessment will screen for this.

If you are looking for a short-term fix before an event, this is the wrong tool. Meaningful change takes months, the medicine costs money throughout, and stopping is commonly followed by regain.

If you cannot sustain the cost, starting and stopping repeatedly is worse than not starting.

If a symptom needs investigating, that comes first. Unexplained weight change, abdominal pain or other symptoms need a diagnosis before a weight-management medicine is layered on top.

Contraindications and cautions across the class

Contraindications and cautions differ by product11, and the current UK Summary of Product Characteristics and the patient information leaflet supplied with your medicine are the authoritative sources. They must be checked individually rather than treated as a single class-wide list.

Known serious hypersensitivity to the medicine or any of its excipients is a formal contraindication.

Treatment may require additional caution, or may be unsuitable, in people with a history of pancreatitis, severe gastrointestinal disease including severe gastroparesis, gallbladder disease, kidney or liver impairment, or diabetic retinopathy. Depending on the product, these appear as warnings, precautions or areas of limited experience rather than as formal contraindications. The distinction matters: it is the difference between a medicine you cannot have and one that needs closer monitoring.

If you have a personal or family history of thyroid disease, raise it at your assessment so your prescriber can consider it against the current UK product information for the specific medicine being discussed.

Pregnancy, breastfeeding and planned pregnancy all require discussion before treatment rather than after. Planned surgery or any procedure requiring sedation or anaesthesia must be disclosed well in advance, because delayed gastric emptying increases aspiration risk.

---

Safety and side effects across the class

Most side effects are gastrointestinal, most appear in the first weeks or after a dose increase, and most settle as the body adjusts. The tables below summarise the common ones; the current patient information leaflet and the BNF entry16 are the authoritative sources for the full profile.

Surgery, sedation and anaesthesia

This is the safety point most often missed, and it can have serious consequences.

These medicines slow gastric emptying. Under sedation or general anaesthesia, that raises the risk of aspiration — stomach contents entering the lungs — even after a standard fasting period, because the stomach may not have emptied as expected.

Tell your surgical and anaesthetic team well in advance of any planned operation or procedure involving sedation, including endoscopy and some dental procedures. Professional guidance on how far ahead to stop varies and continues to develop17, so this is a conversation to have early rather than the day before. Do not stop treatment unilaterally either — coordinate it.

Kidney impairment and dehydration

Gastrointestinal side effects cause fluid loss, and dehydration is the mechanism behind most of the kidney-related problems reported with this class of medicine. Acute kidney injury has been reported in the context of significant vomiting or diarrhoea.

If you have existing kidney impairment, or take medicines whose effect depends on hydration status — diuretics, ACE inhibitors, angiotensin receptor blockers, some anti-inflammatories — this needs individual assessment and may change the monitoring plan.

Practically: dark urine, passing urine much less than usual, dizziness on standing and persistent thirst are the signs to act on. During a period of vomiting or diarrhoea, maintaining fluid intake matters more than maintaining the treatment schedule.

Older adults and frailty

Age alone does not rule out treatment, but several considerations become more important with age.

Muscle mass and sarcopenia. Weight loss from any cause includes some lean tissue. In older adults, who typically have less muscle reserve to begin with, that carries a greater functional cost. Adequate protein and resistance exercise move from advisable to important.

Falls and blood pressure. As weight reduces, antihypertensive medication may become excessive, and dizziness on standing raises fall risk.

Nutritional adequacy. Reduced appetite in someone already eating modestly can tip into inadequate intake more quickly.

Polypharmacy. More medicines means more interaction surface, particularly given the effect on oral absorption.

None of this is a reason not to treat where treatment is appropriate. It is a reason for closer review and a slower, more monitored approach.

---

Realistic expectations

The trial figures quoted throughout this page are averages across studied populations over 68 to 72 weeks, in participants receiving structured dietary support at trial intensity. Four things follow from that.

An average contains a wide spread. Some participants lost considerably more, some considerably less. Publishing a mean figure as though it were an expected individual result is misleading, and it is the single most common way these medicines are misrepresented online.

Trial conditions are not everyday conditions. Participants received regular contact, structured dietary support and monitoring at a level most people do not have.

Time matters. These are 68 to 72-week figures — roughly sixteen months. Results at twelve weeks look very different, and weight loss is rarely linear.

The medicine is licensed as an adjunct. Not as a standalone intervention, and not as a replacement for dietary change, activity or behavioural support14. That word carries real weight: what you eat during the period of reduced appetite determines a great deal about the quality of the weight you lose, how you feel while losing it, and how much of the result you keep.

How long-term success differs from initial weight loss. The patients who do best at two years are frequently not the ones who lost fastest in the first three months. They are the ones who used the period of reduced appetite to build eating patterns they actually wanted to keep, protected muscle with resistance training from early on, and treated the medicine as the thing that made change possible rather than the change itself.

Rapid early loss with no behavioural change is the pattern most associated with regain after stopping. It is worth knowing at the start rather than discovering at month eighteen.

What the pivotal trials actually reported

The table below sets out the headline figures from the pivotal trials side by side. It is included so you can see what was measured, over how long, and in whom — not as a prediction of individual results.

Averages across trial populations receiving structured lifestyle support. Individual results vary widely in both directions. Figures for the two medicines come from different trials except where SURMOUNT-5 compared them directly.

Protecting muscle while losing weight

This is the single most underrated part of treatment, and the part most likely to determine how you feel at the end of it.

Weight loss from any cause includes both fat and lean tissue. Two things substantially limit the lean tissue component: adequate protein intake and resistance exercise. Neither is optional if you want to keep function and metabolic rate rather than simply reducing the number on the scales.

Protein. Requirements vary by body size, age, activity and health status, so a single universal target is not useful and for some people would be actively wrong — anyone with kidney disease in particular must get individual advice before increasing protein. Food first: meat, fish, eggs, dairy, beans, lentils, tofu and pulses. When total intake falls, protein is the thing most worth protecting. See our GLP-1 meal plan and recipe guide.

Resistance exercise. Bodyweight exercises, bands or weights, a couple of times a week, established during treatment rather than after it. This is the biggest protective factor for maintenance after stopping. Our guides on exercising during treatment and protecting muscle go into detail.

Do not crash diet on top. Combining very low calorie intake with a medicine that already substantially reduces intake increases the risk of nutritional deficiency, muscle loss, fatigue, hair thinning and gallstones. The medicine is doing the restriction; adding severe restriction on top is counterproductive rather than accelerating.

No provider can accurately predict how much weight an individual will lose. Published figures describe averages across study populations, not guaranteed personal outcomes.

---

Why pharmacy-led care matters

The weight management market has grown quickly, and a substantial part of it is now run by companies whose core competence is subscription commerce rather than clinical care. The medicine is the same. What surrounds it is not.

A pharmacist’s training is in medicines. Interactions, absorption, formulation, storage, dose adjustment and the practical management of side effects are the substance of the qualification rather than an adjacent interest. In a class of medicines where delayed gastric emptying alters oral drug absorption, where combination with insulin or a sulfonylurea creates hypoglycaemia risk, and where contraceptive efficacy changes at each dose increase, that matters.

Continuity changes outcomes. Side effects managed in week two rarely become the reason someone stops. The same symptoms ignored until week eight usually do. Whether anyone reviews you, and how easily you can reach them, is a better predictor of whether treatment works for you than which medicine you were prescribed.

Named accountability. A registered pharmacy has a superintendent pharmacist who is personally accountable to the regulator for the clinical governance of the service. That accountability is verifiable on the GPhC register, and it is a meaningfully different structure from a platform that contracts prescribing out.

What should happen at a monthly review

Ongoing review is where providers differ most, and knowing what a good one covers lets you judge whether you are getting one.

A proper review should cover how much weight you have lost and over what period; whether side effects are settling, persisting or worsening; whether the current dose is right or whether staying longer is better than escalating; any new symptoms, particularly abdominal pain; any new medicines you have started; whether your other conditions or medicines need reviewing as your weight changes; and your eating pattern, protein intake and activity.

Routine blood monitoring is not universally required for weight-management treatment in the way it is for some medicines. Your prescriber may request baseline or interval tests depending on your circumstances — for example if you have diabetes, kidney or liver concerns, or if a symptom needs investigating. Be cautious of a provider that offers no clinical review at all, and equally of one marketing extensive testing you have not been given a clinical reason for.

Do not wait for a scheduled review to report severe abdominal pain, persistent vomiting, signs of dehydration, symptoms of an allergic reaction or sudden visual changes. Those need attention when they happen.

What Slinic’s service includes

• Online clinical assessment reviewed by a UK-registered prescriber
• Video consultation where required by our clinical pathway
• Prescribing decisions made by GMC- and GPhC-registered clinicians
• Monthly clinical check-ins
• Needles and swabs supplied with your treatment
• No subscription and no minimum term
• Fixed published 2026 prices that do not change mid-treatment
• Access to a pharmacist for clinical questions during treatment
• Discreet UK tracked delivery in insulated packaging with cooling materials appropriate for the journey
• Support for patients transferring from another provider

Slinic dispenses through Brierfield Late Night Pharmacy, GPhC-registered premises No. 1033729, an NHS-contracted community pharmacy. Completing an assessment does not guarantee that treatment will be approved.

---

How to prepare for your consultation

The assessment exists to catch the situations where treatment would be unsafe for you specifically. Completing it properly is what makes it useful — and preparing for it is the most productive thing you can do with the decision you have been researching.

What you will be asked

• Your height and current weight, and how your weight has changed over time
• Previous weight-loss attempts, including any medication
• Your full medical history, including anything you might assume is irrelevant
• Every medicine you take — prescription, over-the-counter, herbal and supplements
• Whether you are pregnant, breastfeeding, or planning a pregnancy
• Any history of eating disorders
• Whether you have any surgery or procedure planned
• Your alcohol intake
• Family history where relevant to the product warnings

What to have ready

• An accurate current weight — weigh yourself rather than estimating
• A list of your medicines, with doses
• Photo ID
• If transferring from another provider: your current dose, how long you have been on it, and evidence such as a dispensing label or order history

Questions worth asking

Which options are clinically appropriate for me specifically, and why. What would make you change that recommendation. How quickly would you escalate my dose, and what would make you slow down. Who reviews me between orders, and how do I reach them. What is the total cost at the dose I am likely to reach. What happens if I want to stop.

---

Frequently asked questions

---

Summary

There is no single best weight loss injection, and the question is better framed as which treatment is appropriate for you. The licensed options differ in mechanism, dosing, administration route and cost, and the evidence shows meaningful differences in average weight reduction between them — but averages describe populations, not people.

What determines the right treatment is your medical history, whether you have type 2 diabetes, every other medicine you take, your previous treatment experience, what you can practically sustain and what you can tolerate. Those factors routinely lead two people with identical BMIs to entirely different recommendations.

Obtaining treatment safely means using a properly regulated UK pharmacy, completing a genuine clinical assessment and being fully honest about your medical history. Price matters, but what happens after the first order matters at least as much.

If you would like to find out whether treatment may be appropriate for you, complete our clinical assessment and a UK-registered prescriber will review it.

Related guides